Gongwin Biopharm Holdings (6617) reported revenue of NT$9.3 million for Oct 2026, +397.3% year on year and +221.7% from the previous month. Revenue for Jan–Oct 2026 was NT$43.2 million (+42.2% year on year).
Revenue for Oct 2026 was a record high (previous high: Sep 2025, NT$5.1 million). →
In Oct 2026, it ranked No. 136 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$9.3 million | +397.3% | +221.7% |
| Sep 2026 | NT$2.9 million | -42.6% | -37.7% |
| Aug 2026 | NT$4.6 million | +7.8% | +1.3% |
| Jul 2026 | NT$4.6 million | +63.5% | +1.8% |
| Jun 2026 | NT$4.5 million | +70.0% | +1.8% |
| May 2026 | NT$4.4 million | +68.5% | +18.0% |
| Apr 2026 | NT$3.8 million | +7.6% | +21.2% |
| Mar 2026 | NT$3.1 million | +11.1% | +11.5% |
| Feb 2026 | NT$2.8 million | +13.4% | -14.4% |
| Jan 2026 | NT$3.2 million | +36.2% | -7.5% |
| Dec 2025 | NT$3.5 million | +30.5% | +35.3% |
| Nov 2025 | NT$2.6 million | -12.5% | +38.3% |
| Oct 2025 | NT$1.9 million | -31.5% | -62.9% |
| Sep 2025 | NT$5.1 million | +82.2% | +17.2% |
| Aug 2025 | NT$4.3 million | +35.7% | +53.7% |
| Jul 2025 | NT$2.8 million | +1.5% | +5.8% |
| Jun 2025 | NT$2.7 million | -29.2% | +0.9% |
| May 2025 | NT$2.6 million | -25.6% | -24.6% |
| Apr 2025 | NT$3.5 million | +41.8% | +25.2% |
| Mar 2025 | NT$2.8 million | +18.7% | +13.8% |
| Feb 2025 | NT$2.4 million | +69.9% | +2.8% |
| Jan 2025 | NT$2.4 million | +40.0% | -11.4% |
| Dec 2024 | NT$2.7 million | -30.7% | -9.3% |
| Nov 2024 | NT$3 million | +36.9% | +8.3% |
| Oct 2024 | NT$2.7 million | +4.8% | -1.3% |
Jan–Oct 2026 cumulative: NT$43.2 million (+42.2% YoY)
Other Biotech & Medical companies
Compare with peers: Gongwin Biopharm Holdings vs PEC / Gongwin Biopharm Holdings vs Lotus Pharm / Gongwin Biopharm Holdings vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
自2018年度起依據國際會計準則公報15號規定認列收入
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16